Business Models

Charter

The Business Models and COGs Subcommittee strives to:

  • Map out the manufacturing process and COGs considerations as they relate to optimizing the Buisness Model, including reimbursement and adoption into standard of care, for both autologous and allogeneic cell therapy products.

Projects and Objectives

  • The Business Models and COGs Subcommittee will collect information from ISCT stakeholders via online surveys to assist in the development of educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing.

 


 


 

Committee Members


 

William Milligan, BSc
Chair
Steminent Biotherapeutics Inc.
Vancouver, BC, Canada

Allen Chen, PhD
ASTAR
Singapore
Suzanne Farid, PhD
University College London
London, England
John Fink, MSc
Brooks Life Science Systems
Chelmsford, MA, United States
 Ian Fitzpatrick, MSc
Iscinogy
Mount Waverley, Victoria, Australia
Yonatan Lipsitz
University of Toronto
Toronto, ON, Canada
Robert Perry
Athersys
Cleveland, OH, United States
Evelien Stalmeijer
eXmoor pharma concepts ltd
Berkshire, United Kingdom
Kah Yong Tan, PhD
ASTAR
Singapore


Allen Chen, PhD
ASTAR
Singapore

© 2015 International Society for Cellular Therapy. All rights reserved.
ISCT, International Society for Cellular Therapy, and the ISCT logo are registered service marks of The International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of The International Society for Cellular Therapy.